European and UK Regulatory Milestones for Novo Nordisk's Oral Wegovy Tablets
The European Commission (EC) has formally granted marketing authorization for Novo Nordisk's oral Wegovy (semaglutide) tablet on July 15, 2026, marking a critical milestone in the global expansion of oral GLP-1 receptor agonists. This approval establishes oral Wegovy as the first and only once-daily weight-loss pill cleared EU-wide for adults with obesity or overweight and at least one weight-related comorbidity.
Alongside the oral formulation, the European Commission concurrently approved a high-dose, 7.2-mg version of the injectable Wegovy pen. This high-dose formulation, which received FDA approval in March 2026, was evaluated in the 72-week Step Up trial, demonstrating an average weight loss of 20.7% compared to 17.5% for the standard 2.4-mg dose and 2.4% for placebo.
Clinical and Commercial Implications
The EU approval of oral Wegovy completes a clean sweep of first-mover regulatory victories for Novo Nordisk across the US (January 2026), the UK (June 2026), and now continental Europe.
- Clinical Efficacy: In the OASIS clinical trials, a once-daily 25-mg dose of oral Wegovy achieved an average weight loss of 17% (compared to 3% for placebo), with approximately one-third of participants losing at least 20% of their body weight.
- Widening Commercial Gap: While Eli Lilly's competitive oral non-peptide GLP-1 receptor agonist, Foundayo (orforglipron), secured FDA approval in April 2026, Lilly has not yet filed for regulatory approval of Foundayo in Europe, with a launch not anticipated until late 2026 or 2027.
- US Market Performance: Novo Nordisk's oral Wegovy pill has logged one of the strongest volume launches on record in the US, surpassing 3 million prescriptions in its first five months (averaging one prescription filled every five seconds). Weekly IQVIA data from July 2026 shows oral Wegovy logging 153,000 weekly US prescriptions, compared to 19,550 weekly prescriptions for Lilly's Foundayo in its 13th week on the market.
This regulatory head start positions Novo Nordisk to dominate the European cash-pay and reimbursement markets before Eli Lilly can establish a physical foothold with Foundayo.